A Study to Evaluate the Drug Levels, Metabolism, and Removal of BMS-986322 in Healthy Adult Male Participants

A Phase 1, Single-center, Open-label Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of [14C] BMS-986322 in Healthy Adult Male Participants

The purpose of this study is to evaluate the drug levels, metabolism, and removal of BMS-986322 in healthy adult male participants.

Inclusion Criteria:

• Participants must have a body mass index of 18.0 to 32.0 kg/m2, inclusive.
• Participants will be required to always use a latex or other synthetic condom with spermicide during any sexual activity
• Participants must refrain from donating sperm during the entire study and for at least 90 days from dose of study drug.

Exclusion Criteria:

• Participant must not have had any clinically significant diagnostic or therapeutic radiation exposure within the previous 12 months prior to admission to the clinic.
• Participant must not be currently employed in a job requiring radiation exposure monitoring.
• Participant must not have had any major surgery within 4 weeks of study drug administration that could impact upon the absorption of study drug